The Selective Adenosine 2B Receptor Antagonist MRS1754 Mitigates Hepatic Collagen Deposition During Fibrosis Progression and Induces Mild Fibrosis Regression

被引：0

|

作者：

Stoll, Matthias

Kim, Yong Ook

Hebich, Bernhard

Robson, Simon C.

Schuppan, Detlef

机构：

来源：

GASTROENTEROLOGY | 2012年 / 142卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：S974 / S975

页数：2

相关论文

共 9 条

[1] TREATMENT WITH THE SELECTIVE ADENOSINE 2B RECEPTOR ANTAGONIST MRS1754 RESULTS IN ALLEVIATED HEPATIC COLLAGEN DEPOSITION DURING FIBROSIS PROGRESSION
Stoll, M.
Kim, Y. O.
Hebig, B.
Schuppan, D.
JOURNAL OF HEPATOLOGY, 2012, 56 : S160 - S160
[2] EFFECT OF ADENOSINE 2B RECEPTOR ANTAGONIST MRS1754 ON FIBROSIS PROGRESSION AND REGRESSION IN MICE
Resa, T. C.
Kim, Y. O.
Stoll, M.
Robson, S.
Schuppan, D.
JOURNAL OF HEPATOLOGY, 2013, 58 : S461 - S461
[3] MRS 1754, a selective A2B adenosine receptor antagonist, inhibits degranulation of cultured human butnotmurine mast cells
Kirshenbaum, AS
Hettinger, B
Day, YJ
Gilfillan, AM
Metcalfe, DD
Kim, YC
Linden, J
Jacobson, KA
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S281 - S281
[4] An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis
Wenglen, Christina
Arozenius, Helena
Pettersson, Lars
Ekstrom, Gunilla
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[5] A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Wenglen, Christina
Pettersson, Lars
Arozenius, Helena
Ekstrom, Gunilla
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[6] A NOVEL HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
Wenglen, C.
Pettersson, L.
Arozenius, H.
Ekstrom, G.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 891 - 891
[7] A New Highly Selective 5-Hydroxytryptamine 2b (5-Ht2b) Receptor Antagonist With Anti-Fibrotic Effects In Models Of Lung Fibrosis
Wenglen, C.
Pettersson, L.
Arozenius, H.
Ekstrom, G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
[8] An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis
Wenglen, Christina
Arozenius, Helena
Pettersson, Lars
Ekstrom, Gunilla
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[9] AN ORALLY AVAILABLE HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING PULMONARY AND DERMAL FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
Wenglen, Christina
Arozenius, Helena
Pettersson, Lars
Ekstrom, Gunilla
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 457 - 458